Use of cabotegravir in HIV prevention during pregnancy: A literature review
DOI:
https://doi.org/10.33448/rsd-v13i10.47134Keywords:
Pregnant, Anti-Retroviral Agents, Pre-exposure prophylaxis.Abstract
The Human Immunodeficiency Virus (HIV), the causative agent of Acquired Immunodeficiency Syndrome (AIDS), remains a significant global challenge, with millions of cases and deaths since its discovery in the 1980s, predominantly affecting women and girls. Antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP) are crucial tools in the fight against HIV, with injectable cabotegravir (CAB-LA) emerging as a new long-acting PrEP option. However, the safety and efficacy of CAB-LA during pregnancy remain poorly understood, with limited data available. The objective of this study was to conduct a literature review on the safety of CAB-LA administration in pregnant women using PrEP. The methodology of this study included a comprehensive search of electronic databases, such as the National Library of Medicine (PubMed), Scopus, Embase, Web of Science, and official websites, restricted to english and portuguese languages. The results show that while CAB-LA has demonstrated good tolerance and efficacy in non-pregnant adults, its long half-life and persistence in the body, in addition to low placental transfer, present challenges for its use in pregnant women. Further studies and detailed pre-conception counseling are essential to better understand the risks and benefits of CAB-LA during pregnancy. This review indicates that until more data is available, the use of CAB-LA during pregnancy should be approached with caution and individualized consideration.
Downloads
References
Atoyebi, S., Bunglawala, F., Cottura, N., Grañana-Castillo, S., Montanha, M. C., Olagunju, A., Siccardi, M., & Waitt, C. (2024). Physiologically-based pharmacokinetic modelling of long-acting injectable cabotegravir and rilpivirine in pregnancy. British journal of clinical pharmacology, 10.1111/bcp.16006. Advance online publication. https://doi.org/10.1111/bcp.16006
Atta, M. G., De Seigneux, S., & Lucas, G. M. (2019). Clinical Pharmacology in HIV Therapy. Clinical journal of the American Society of Nephrology : CJASN, 14(3), 435–444. https://doi.org/10.2215/CJN.02240218
Brooks, K. M., Scarsi, K. K., & Mirochnick, M. (2023). Antiretrovirals for Human Immunodeficiency Virus Treatment and Prevention in Pregnancy. Obstetrics and gynecology clinics of North America, 50(1), 205–218. https://doi.org/10.1016/j.ogc.2022.10.013
Casarin, S. T. et al. (2020). Tipos de revisão de literatura: considerações das editoras do Journal of Nursing and Health/Types of literature review: considerations of the editors of the Journal of Nursing and Health. Journal of Nursing and Health. 10 (5). DOI: https://doi.org/10.15210/jonah.v10i5.19924
Cavalcante, L. T. C. & Oliveira, A. A. S. (2020). Métodos de revisão bibliográfica nos estudos científicos. Psicol. Rev. 26 (1). https://doi.org/10.5752/P.1678-9563.2020v26n1p82-100
CDC. (2024). Unintended Pregnancy. https://www.cdc.gov/reproductive-health/hcp/unintended-pregnancy/index.html
Chen, X., Li, J., Kou, L., Xie, X., Wei, D., & Li, Y. (2023). Efficacy and safety of long-acting cabotegravir versus oral tenofovir disoproxil fumarate-emtricitabine as HIV pre-exposure prophylaxis: A systematic review and meta-analysis. Reviews in medical virology, 33(4), e2460. https://doi.org/10.1002/rmv.2460
Durham, S. H., Milam, A., Waer, D., & Chahine, E. B. (2023). Cabotegravir: The First Long-Acting Injectable for HIV Preexposure Prophylaxis. The Annals of pharmacotherapy, 57(3), 306–316. https://doi.org/10.1177/10600280221102532
Fairlie, L., Lavies, D., Kalk, E., Mhlongo, O., Patel, F., Technau, K. G., Mahtab, S., Moodley, D., Subedar, H., Mullick, S., Sawry, S., & Mehta, U. (2023). Safety surveillance for PrEP in pregnant and breastfeeding women. Frontiers in reproductive health, 5, 1221101. https://doi.org/10.3389/frph.2023.1221101
Food and Drug Administration. (2022). Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Integrase. Inhibitors. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212888s000lbl.pdf
Global Health Policy. (2024). The Global HIV/AIDS Epidemic, https://www.kff.org/global-health-policy/fact-sheet/the-global-hiv-aids-epidemic/
Johnson, L. F., Myer, L., Jamieson, L., Meyer-Rath, G., Delany-Moretlwe, S., & Joseph Davey, D. (2024). The potential benefits of long-acting injectable cabotegravir in pregnant and breastfeeding women and their infants. AIDS (London, England), 38(4), 589–594. https://doi.org/10.1097/QAD.0000000000003803
Kemnic, TR e Gulick, PG. (2022). HIV Antiretroviral Therapy. StatPearls. https ://www.ncbi.nlm.nih.gov/livros/NBK
Ministério da Saúde. (2024). Departamento de HIV, Aids, Tuberculose, Hepatites Virais e Infecções Sexualmente Transmissíveis. https://www.gov.br/aids/pt-br/assuntos/hiv-aids/tratamento
Organização Mundial da Saúde. (2021). Consolidated guidelines on hiv prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. https://www.who.int/publications/i/item/9789240031593
Patel, P., Thiagarajah, S., Ford, S L, Margolis, D A, Romach, B., Baker, M., Sutton, K., Harrington, C., Shaefer, M., Spreen, W R, Smith, K Y, & Vannappagari, V. (2020, 8 - 11 march). Cabotegravir pharmacokinetic tail in pregnancy and neonatal outcomes. Conference on Retroviruses and Opportunistic Infections (CROI).
Patel P., Thiagarajah, S., Ford S L, Margolis, D A, Romach B., Baker M., Sutton, K., Harrington, C., Shaefer M., Spreen, W R, Smith, K Y, & Vannappagari V . (2024, 10 - 13 march) Cabotegravir pharmacokinetic tail in pregnancy and neonatal outcomes. Conference on Retroviruses and Opportunistic Infections (CROI).
Pencolé, L., Lê, M. P., Bouchet-Crivat, F., Duro, D., Peytavin, G., & Mandelbrot, L. (2020). Placental transfer of the integrase strand inhibitors cabotegravir and bictegravir in the ex-vivo human cotyledon perfusion model. AIDS (London, England), 34(14), 2145–2149. https://doi.org/10.1097/QAD.0000000000002637
Pereira A. S. et al. (2018). Metodologia da pesquisa científica. [free e-book]. Santa Maria/RS. Ed. UAB/NTE/UFSM.
Prather, C., & Jeon, C. (2022). Cabotegravir: The first long-acting injectable for HIV pre-exposure prophylaxis. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 79(21), 1898–1905. https://doi.org/10.1093/ajhp/zxac201
Rother, E. T. (2007). Revisão sistemática x revisão narrativa. Acta paul. enferm. 20 (2). https://doi.org/10.1590/S0103-21002007000200001
Sahloff, E. G., Hamons, N., Baumgartner, K., & Duggan, J. M. (2022). Is Long-acting Cabotegravir a Pre-exposure Prophylaxis Option for Women of Childbearing Potential?. Open forum infectious diseases, 9(7), ofac230. https://doi.org/10.1093/ofid/ofac230
Smith, M. R., Mohan, H., Ajaykumar, A., Hsieh, A. Y. Y., Martineau, L., Patel, R., Gadawska, I., Sherwood, C., Serghides, L., Piret, J. M., & Côté, H. C. F. (2022). Second-Generation Human Immunodeficiency Virus Integrase Inhibitors Induce Differentiation Dysregulation and Exert Toxic Effects in Human Embryonic Stem Cell and Mouse Models. The Journal of infectious diseases, 226(11), 1992–2001. https://doi.org/10.1093/infdis/jiac386
UNAIDS. (2024). Estatísticas. https://unaids.org.br/estatisticas/
van der Galiën, R., Ter Heine, R., Greupink, R., Schalkwijk, S. J., van Herwaarden, A. E., Colbers, A., & Burger, D. M. (2019). Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps. Clinical pharmacokinetics, 58(3), 309–323. https://doi.org/10.1007/s40262-018-0684-z
Zizioli, D., Zanella, I., Mignani, L., Degli Antoni, M., Castelli, F., & Quiros-Roldan, E. (2023). Cabotegravir Exposure of Zebrafish (Danio rerio) Embryos Impacts on Neurodevelopment and Behavior. International journal of molecular sciences, 24(3), 1994. https://doi.org/10.3390/ijms24031994
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Allyne Cristina Grando; Rafael Rodrigues Dihl
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
